Literature DB >> 29948757

Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis.

Babikir Kheiri1, Tarek Haykal1, Ahmed Abdalla1, Mohammed Osman1, Sahar Ahmed2, Khansa Osman2, Ghassan Bachuwa1, Mustafa Hassan1, Deepak L Bhatt3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29948757     DOI： 10.1007/s11239-018-1694-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  15 in total

Review 1.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

2.  Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.

Authors:  Rangadham Nagarakanti; Michael D Ezekowitz; Jonas Oldgren; Sean Yang; Michael Chernick; Timothy H Aikens; Greg Flaker; Josep Brugada; Gabriel Kamensky; Amit Parekh; Paul A Reilly; Salim Yusuf; Stuart J Connolly
Journal:  Circulation       Date:  2011-01-03       Impact factor: 29.690

3.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas
Journal:  Eur Heart J       Date:  2016-08-27       Impact factor: 29.983

4.  Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.

Authors:  Riccardo Cappato; Michael D Ezekowitz; Allan L Klein; A John Camm; Chang-Sheng Ma; Jean-Yves Le Heuzey; Mario Talajic; Maurício Scanavacca; Panos E Vardas; Paulus Kirchhof; Melanie Hemmrich; Vivian Lanius; Isabelle Ling Meng; Peter Wildgoose; Martin van Eickels; Stefan H Hohnloser
Journal:  Eur Heart J       Date:  2014-09-02       Impact factor: 29.983

5.  Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.

Authors:  Andreas Goette; Jose L Merino; Michael D Ezekowitz; Dmitry Zamoryakhin; Michael Melino; James Jin; Michele F Mercuri; Michael A Grosso; Victor Fernandez; Naab Al-Saady; Natalya Pelekh; Bela Merkely; Sergey Zenin; Mykola Kushnir; Jindrich Spinar; Valeriy Batushkin; Joris R de Groot; Gregory Y H Lip
Journal:  Lancet       Date:  2016-08-30       Impact factor: 79.321

6.  Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.

Authors:  Jonathan P Piccini; Susanna R Stevens; Yuliya Lokhnygina; Manesh R Patel; Jonathan L Halperin; Daniel E Singer; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Günter Breithardt
Journal:  J Am Coll Cardiol       Date:  2013-03-14       Impact factor: 24.094

7.  Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion.

Authors:  Saga Itäinen; Mika Lehto; Tuija Vasankari; Pirjo Mustonen; Mervi Kotamäki; Anna Numminen; Heli Lahtela; Aissa Bah; Juha Hartikainen; Anna-Mari Hekkala; Juhani K E Airaksinen
Journal:  Europace       Date:  2018-04-01       Impact factor: 5.214

Review 8.  Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.

Authors:  Caitlin M Gibson; Amanda N Basto; Meredith L Howard
Journal:  Ann Pharmacother       Date:  2017-10-12       Impact factor: 3.154

9.  Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry.

Authors:  Judit Papp; Endre Zima; Ramon Bover; Rasa Karaliute; Andrea Rossi; Catherine Szymanski; Rossella Troccoli; Jonas Schneider; Morten Wang Fagerland; A John Camm; Dan Atar
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2017-07-01

10.  Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.

Authors:  Michael D Ezekowitz; Charles V Pollack; Jonathan L Halperin; Richard D England; Sandra VanPelt Nguyen; Judith Spahr; Maria Sudworth; Nilo B Cater; Andrei Breazna; Jonas Oldgren; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2018-08-21       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.